期刊文献+

Lowered testosterone in male obesity: mechanisms, morbidity and management 被引量:33

【特刊综述】肥胖男性低睾酮的发生机制、发病率及其处理
下载PDF
导出
摘要 With increasing modernization and urbanization of Asia, much of the future focus of the obesity epidemic will be in the Asian region. Low testosterone levels are frequently encountered in obese men who do not otherwise have a recognizable hypothalamic-pituitary-testicular (HPT) axis pathology. Moderate obesity predominantly decreases total testosterone due to insulin resistance-associated reductions in sex hormone binding globulin. More severe obesity is additionally associated with reductions in free testosterone levels due to suppression of the HPT axis. Low testosterone by itself leads to increasing adiposity, creating a self-perpetuating cycle of metabolic complications. Obesity-associated hypotestosteronemia is a functional, non-permanent state, which can be reversible, but this requires substantial weight loss. While testosterone treatment can lead to moderate reductions in fat mass, obesity by itself, in the absence of symptomatic androgen deficiency, is not an established indication for testosterone therapy. Testosterone therapy may lead to a worsening of untreated sleep apnea and compromise fertility. Whether testosterone therapy augments diet- and exercise-induced weight loss requires evaluation in adequately designed randomized controlled clinical trials. With increasing modernization and urbanization of Asia, much of the future focus of the obesity epidemic will be in the Asian region. Low testosterone levels are frequently encountered in obese men who do not otherwise have a recognizable hypothalamic-pituitary-testicular (HPT) axis pathology. Moderate obesity predominantly decreases total testosterone due to insulin resistance-associated reductions in sex hormone binding globulin. More severe obesity is additionally associated with reductions in free testosterone levels due to suppression of the HPT axis. Low testosterone by itself leads to increasing adiposity, creating a self-perpetuating cycle of metabolic complications. Obesity-associated hypotestosteronemia is a functional, non-permanent state, which can be reversible, but this requires substantial weight loss. While testosterone treatment can lead to moderate reductions in fat mass, obesity by itself, in the absence of symptomatic androgen deficiency, is not an established indication for testosterone therapy. Testosterone therapy may lead to a worsening of untreated sleep apnea and compromise fertility. Whether testosterone therapy augments diet- and exercise-induced weight loss requires evaluation in adequately designed randomized controlled clinical trials.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第2期223-231,I0008,共10页 亚洲男性学杂志(英文版)
关键词 ANDROGENS HYPOGONADISM OBESITY TESTOSTERONE weight loss androgens hypogonadism obesity testosterone weight loss
  • 相关文献

参考文献3

二级参考文献58

  • 1Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al;Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-59.
  • 2Wu FC, Tajar A, Beynon JM, Pye SR, Silman A J, et al; EMAS group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-35.
  • 3Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
  • 4Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
  • 5Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50.
  • 6Travison TG, Araujo AB, Hall SA, McKinlay JB. Temporal trends in testosterone levels and treatment in older men. Curt Opin Endocrinol Diabetes Obes 2009; 16: 211-7.
  • 7Borell M. Brown-Sequard's organotherapy and its appearance in America at the end of the hineteenth century. Bull'Hist Med 1976; 50: 309-20.
  • 8Borell M. Organotherapy, British physiology, and discovery of the internal secretions. J Hist Biol 1976: 9: 235-68.
  • 9Kahn A. Regaining lost youth: the dontroversial and colorful beginnings of hormone replacement therapy in aging. J Gerontol A Biol Sci Med Sci 2005; 60: 142-7.
  • 10Cussons A J, Bhagat CI, Fletcher S J, Walsh JP. Brown- Sequard revisited: a lesson from history on the placebo effect of androgen treatment. MeddAust2002; 177: 678-9.

共引文献14

同被引文献192

引证文献33

二级引证文献173

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部